181 related articles for article (PubMed ID: 35904608)
1. Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study.
Liu Y; Wang Y; Zhang W
EJNMMI Res; 2022 Jul; 12(1):45. PubMed ID: 35904608
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
3. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
[TBL] [Abstract][Full Text] [Related]
4. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.
Li G; Lei J; Song L; Jiang K; Wei T; Li Z; Gong R; Zhu J
Cancer Med; 2018 Nov; 7(11):5448-5456. PubMed ID: 30264548
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.
Kang SY; Bang JI; Kang KW; Lee HY; Chung JK
PLoS One; 2019; 14(6):e0218416. PubMed ID: 31237886
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
Cheng L; Fu H; Jin Y; Sa R; Chen L
Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
[TBL] [Abstract][Full Text] [Related]
8.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
9. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
[TBL] [Abstract][Full Text] [Related]
12. Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
Luo Y; Jiang H; Xu W; Wang X; Ma B; Liao T; Wang Y
Front Oncol; 2020; 10():549882. PubMed ID: 33117686
[No Abstract] [Full Text] [Related]
13. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [
Albano D; Tulchinsky M; Dondi F; Mazzoletti A; Lombardi D; Bertagna F; Giubbini R
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):461-468. PubMed ID: 32794104
[TBL] [Abstract][Full Text] [Related]
14. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
15. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
16. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and
Araz M; Soydal Ç; Özkan E; Akkuş P; Nak D; Küçük NÖ; Kır KM
Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
[No Abstract] [Full Text] [Related]
17. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.
Schubert L; Mbekwe-Yepnang AM; Wassermann J; Braik-Djellas Y; Jaffrelot L; Pani F; Deniziaut G; Lussey-Lepoutre C; Chereau N; Leenhardt L; Bernier MO; Buffet C
J Endocrinol Invest; 2024 Apr; ():. PubMed ID: 38578580
[TBL] [Abstract][Full Text] [Related]
18. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract][Full Text] [Related]
19. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a predictive nomogram for differentiated thyroid cancer: an inpatient-based retrospective study.
Du J; Li W; Zhao X; Shen C; Zhang X
Endokrynol Pol; 2023; 74(6):. PubMed ID: 37994582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
